Sugi Predict

Sugi Predict / Compounds / SCHEMBL2933925

SCHEMBL2933925

SCHEMBL2933925

CCCC1CCC(=O)OC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 3/20 0.42
▸ CYP2D6 P10635 1/20 0.37
▸ CA1 P00915 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ LMNA P02545 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ KMT2A Q03164 1/20 0.34
▸ MAPT P10636 1/20 0.33
▸ NOS3 P29474 5/20 0.32
▸ NOS1 P29475 5/20 0.32
▸ NOS2 P35228 5/20 0.32
▸ TLR4 O00206 3/20 0.32
▸ CHRM5 P08912 3/20 0.32
▸ CHRM2 P08172 2/20 0.31
▸ CHRM4 P08173 2/20 0.31
▸ CHRM1 P11229 2/20 0.31
▸ CHRM3 P20309 2/20 0.31
▸ DRD2 P14416 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30996494 0.90 CYP1A2 (0.50) CYP1A2CYP2D6CA1CA9TP53
SCHEMBL2927985 0.89 CYP1A2 (0.57) CYP1A2CYP2D6ALDH1A1KMT2ATLR4
SCHEMBL20357371 0.88 CYP2D6 (0.46) CYP1A2CYP2D6CA1CA9ALDH1A1
SCHEMBL30915400 0.87 CYP1A2 (0.56) CYP1A2ALDH1A1KMT2ATLR4CHRM5
SCHEMBL30915401 0.87 CYP1A2 (0.56) CYP1A2ALDH1A1KMT2ATLR4CHRM5
SCHEMBL2933689 0.87 CYP1A2 (0.56) CYP1A2ALDH1A1KMT2ATLR4CHRM5
SCHEMBL31558673 0.87 CYP1A2 (0.56) CYP1A2ALDH1A1KMT2ATLR4CHRM5
SCHEMBL2927438 0.87 CYP1A2 (0.56) CYP1A2ALDH1A1KMT2ATLR4CHRM5
SCHEMBL5528652 0.85 — —
SCHEMBL12200658 0.85 CYP1A2 (0.39) CYP1A2CYP2D6CA1CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4519404-A1 METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN Firmenich SA (CH) 2025-03-12 — — EP disclosed
EP-4514477-A1 FRAGRANCE COMPOSITIONS HAVING LONG-LASTING TRAIL PERFORMANCE Firmenich SA (CH) 2025-03-05 — — EP disclosed
CN-119486703-A Fragrance composition with lasting fragrance appearance 弗门尼舍有限公司 2025-02-18 — — CN disclosed
CN-119403908-A Method for enhancing psychological performance and composition for use in the method 弗门尼舍有限公司 2025-02-07 — — CN disclosed
WO-2023247599-A1 FRAGRANCE COMPOSITIONS HAVING LONG-LASTING TRAIL PERFORMANCE FIRMENICH SA (CH) 2023-12-28 — — WO disclosed
WO-2023247604-A1 METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN FIRMENICH SA (CH) 2023-12-28 — — WO disclosed
CN-115960074-A Fluorine-containing ferroelectric liquid crystal molecules containing heteroatom hexatomic alicyclic ring and synthesis method thereof 华南理工大学 2023-04-14 — — CN disclosed
US-9879182-B2 Liquid crystal compound having xanthene skeleton and exhibiting negative dielectric anisotropy, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2018-01-30 — — US disclosed
US-20160222295-A1 LIQUID CRYSTAL COMPOUND AND LIQUID CRYSTAL COMPOSITION EMPLOYING THE SAME DAXIN MATERIALS CORPORATION (TW) 2016-08-04 — — US disclosed
US-20160222295-A1 LIQUID CRYSTAL COMPOUND AND LIQUID CRYSTAL COMPOSITION EMPLOYING THE SAME DAXIN MATERIALS CORPORATION (TW) 2016-08-04 — — US disclosed
US-7344761-B2 Liquid-crystalline compounds MERCK PATENT GESELLASCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-03-18 — — US disclosed
US-7344761-B2 Liquid-crystalline compounds MERCK PATENT GESELLASCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-03-18 — — US disclosed
US-20080032914-A1 Beta-Substituted Tetrahdropyrana (On) S And Method For The Synthesis And The Use Thereof V. MANE FILS (FR) 2008-02-07 — — US disclosed
US-7291367-B2 Liquid-crystalline compounds MERCK PATENT GMBH (DE) 2007-11-06 — — US disclosed
US-7291367-B2 Liquid-crystalline compounds MERCK PATENT GMBH (DE) 2007-11-06 — — US disclosed
EP-1565540-B1 LIQUID CRYSTALLINE COMPOUNDS MERCK PATENT GMBH (DE) 2007-09-26 — — EP disclosed
EP-1773284-A1 BETA-SUBSTITUTED TETRAHYDROPYRAN(ON)S AND METHOD FOR THE SYNTHESIS AND THE USE THEREOF V. Mane Fils (FR) 2007-04-18 — — EP disclosed
US-20070034828-A1 Containing 3 directly connected rings: a fluorophenyl ring, a tetrahydropyran ring and either another tetrahydropyran ring or a 1,3-dioxane ring; electrooptical displays; MERCK PATENT GMBH (DE) 2007-02-15 — — US disclosed
US-20070034828-A1 Containing 3 directly connected rings: a fluorophenyl ring, a tetrahydropyran ring and either another tetrahydropyran ring or a 1,3-dioxane ring; electrooptical displays; MERCK PATENT GMBH (DE) 2007-02-15 — — US disclosed
WO-2006021663-A1 BETA-SUBSTITUTED TETRAHYDROPYRAN(ON)S AND METHOD FOR THE SYNTHESIS AND THE USE THEREOF V. MANE FILS (FR) 2006-03-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222295-A1 LIQUID CRYSTAL COMPOUND AND LIQUID CRYSTAL COMPOSITION EMPLOYING THE SAME ZYX, MLX, NPM1 CYP1A2 1185/4885CYP2D6 2968/4885CA1 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.